External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

Angiogenesis 2022

-
Coming soon
09:40 AM
Duration 8mins Virtual
2-Year Outcomes From the Phase 3 Archway Trial: Management of Neovascular Age-Related Macular Degeneration Using the Port Delivery System With Ranibizumab (PDS)
Wykoff C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:48 AM
10:28 AM
Duration 8mins Virtual
Overview of Faricimab for Exudative Retinal Diseases: Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion
Heier J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:36 AM
Duration 8mins Virtual
Faricimab in Neovascular Age-Related Macular Degeneration: Updated Week 48 Results From the Phase 3 TENAYA and LUCERNE Trials
Guymer R*, Demetriades AM, Quezada Ruiz C, Silverman D, Ives J, Basu K, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:44 AM
Duration 8mins Virtual
Faricimab in Diabetic Macular Edema: Two-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Wells J*, Asik K, Haskova Z, Ives J, Silverman D, Tang Y, Lin H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar